Turing Pharmaceuticals, which took a PR and financial beating after plans to exponentially raise the price of one of its drugs, has hired Washington help.Turing on Sept. 29 brought in lobbying and law firm Buchanan Ingersoll & Rooney for "strategy development" and to implement a government relations program.
The New York Times ignitied a firestorm around Turing last month, covering the 5,000 percent price increase of its drug Daraprim from $13 to $750. Chief communications officer Craig Rothenberg, a Johnson & Johnson alum, exited the company amid the crisis, which saw the company retreat on the planned price hike.
The flap has raised eyebrows in Washington and tossed around in the presidential primary season, as well.
Edward Allera, a managing parnter of K-street based BI&R, is co-chair of the firm's Food and Drug Administration section and is a former associate chief counsel of the FDA.
Ripp Media is supporting Turing on the PR front.
Lo Isidro, senior director at Real Chemistry with more than a decade of strategic communications and PA experience, has joined Narrative Strategies.
Nelson Fernandez, former North American chair of APCO Worldwide and managing director of Burson-Marsteller, has joined Volunteers in Medicine Berkshires as director of communications and PA.
Lilit Bargar, who was most recently an EVP in the healthcare practice at Weber Shandwick, comes on board at GCI Health as EVP, corporate practice lead.
Five ways that successful thought leaders are made.
Have a comment? Send it to 
No comments have been submitted for this story yet.